Although pharmacogenetic studies in Latin American populations remain limited, research conducted in Mexican kidney transplant recipients similarly showed that CYP3A5 genotype is strongly associated with tacrolimus pharmacokinetic variability. The gene discussed is CYP3A5; the disease is medical procedure.